Throughout the COVID-19 pandemic, Saint Luke’s Health System is committed to providing exceptional care for all patients and a safe and healthy atmosphere for our team.

Among patients with heart failure, empagliflozin lowered diastolic pulmonary artery pressure and was effective at reducing cardiovascular death and heart failure hospitalizations regardless of sacubitril/valsartan use, researchers reported.

Dr. Mikhail Kosiborod, vice president of research at Saint Luke's Health System, detailed the results of the EMBRACE-HF study looking at the impact of empagliflozin in patients with heart failure and higher diastolic pulmonary artery pressure.

Read the full Healio article: Two studies provide further positive outcomes for empagliflozin in HF

Read more >

Related Content

Person, Doctor, Clothing, Apparel, Lab Coat, Coat, Face, Nurse
Deb's story

Deb Day, Registered Nurse · Anderson County Hospital I am a Saint Luke's Nurse The room to grow, the tools to succeed Nurses are the lifeblood of Saint Luke’s compassionate...

Read more >
Apparel, Clothing, Coat, Lab Coat, Person, Doctor
Danielle's story

"You get those rare moments that you're reminded why you went into this field, and it makes everything so much better." Danielle Hammontree, Certified Family Nurse PractitionerSaint Luke’s East Hospital

Read more >
Person, Text, Female, Clothing, Apparel, Worker, Woman
Brenda's story

"We were able to sustain her long enough so she could make that closure with her family." Brenda Messer, Registered NurseSaint Luke’s Hospital of Kansas City

Read more >